Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

References

• Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972;177:705–706.
   PubMed Web of Science ®Google Scholar
• Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007;20:23–38.
   PubMed Web of Science ®Google Scholar
• Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci 2006;63:832–842.
   PubMed Web of Science ®Google Scholar
• Hong Z, Cameron CE. Pleiotropic mechanisms of ribavirin antiviral activities. Prog Drug Res 2002;59:41–69.
   PubMedGoogle Scholar
• Parker WB. Metabolism and antiviral activity of ribavirin. Virus Res 2005;107:165–171.
   PubMed Web of Science ®Google Scholar
• Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA 2004;101:18105–18110.
   PubMed Web of Science ®Google Scholar
• Kentsis A, Volpon L, Topisirovic I, et al Further evidence that ribavirin interacts with eIF4E. RNA 2005;11:1762–1766.
   PubMed Web of Science ®Google Scholar
• Assouline S, Culjkovic B, Cocolakis E, et al Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 2009;114:257–260.
   PubMed Web of Science ®Google Scholar
• Borden KL. Pondering the puzzle of PML (promyelocytic leukemia) nuclear bodies: can we fit the pieces together using an RNA regulon? Biochim Biophys Acta 2008;1783:2145–2154.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.
   PubMed Web of Science ®Google Scholar
• Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer 2003;3:179–192.
   PubMed Web of Science ®Google Scholar
• Culjkovic B, Borden KL. Understanding and targeting the eukaryotic translation initiation factor eIF4E in head and neck cancer. J Oncol 2009;2009:981679.
   PubMedGoogle Scholar
• Topisirovic I, Guzman ML, McConnell MJ, et al Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol 2003;23:8992–9002.
   PubMed Web of Science ®Google Scholar
• Topisirovic I, Kentsis A, Perez JM, Guzman ML, Jordan CT, Borden KL. Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Mol Cell Biol 2005;25:1100–1112.
   PubMed Web of Science ®Google Scholar
• Wendel HG, De Stanchina E, Fridman JS, et al Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332–337.
   PubMed Web of Science ®Google Scholar
• Ruggero D, Montanaro L, Ma L, et al The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004;10:484–486.
   PubMed Web of Science ®Google Scholar
• Graff JR, Zimmer SG. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 2003;20:265–273.
   PubMed Web of Science ®Google Scholar
• Oridate N, Kim HJ, Xu X, Lotan R. Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin. Cancer Biol Ther 2005;4:318–323.
   PubMed Web of Science ®Google Scholar
• Dong K, Wang R, Wang X, et al Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Breast Cancer Res Treat 2009;113:443–456.
   PubMed Web of Science ®Google Scholar
• Tan A, Bitterman P, Sonenberg N, Peterson M, Polunovsky V. Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1. Oncogene 2000;19:1437–1447.
   PubMed Web of Science ®Google Scholar
• Li S, Takasu T, Perlman DM, et al Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem 2003;278:3015–3022.
   PubMed Web of Science ®Google Scholar
• Polunovsky VA, Rosenwald IB, Tan AT, et al Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol Cell Biol 1996;16:6573–6581.
   PubMed Web of Science ®Google Scholar
• Culjkovic B, Topisirovic I, Borden KL. Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E. Cell Cycle 2007;6:65–69.
   PubMed Web of Science ®Google Scholar
• Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KL. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. EMBO J 2001;20:4547–4559.
   PubMed Web of Science ®Google Scholar
• Strudwick S, Borden KL. The emerging roles of translation factor eIF4E in the nucleus. Differentiation 2002;70:10–22.
   PubMed Web of Science ®Google Scholar
• Sonenberg N, Gingras AC. The mRNA 5’ cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 1998;10:268–275.
   PubMed Web of Science ®Google Scholar
• Topisirovic I, Culjkovic B, Cohen N, Perez JM, Skrabanek L, Borden KL. The proline-rich homeodomain protein, PRH, is a tissue-specific inhibitor of eIF4E-dependent cyclin D1 mRNA transport and growth. EMBO J 2003;22:689–703.
   PubMed Web of Science ®Google Scholar
• Kentsis A, Dwyer EC, Perez JM, et al The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E. J Mol Biol 2001;312:609–623.
   PubMed Web of Science ®Google Scholar
• Kentsis A, Gordon RE, Borden KL. Control of biochemical reactions through supramolecular RING domain self-assembly. Proc Natl Acad Sci USA 2002;99:15404–15409.
   PubMed Web of Science ®Google Scholar
• Volpon L, Osborne MJ, Capul AA, de la Torre JC, Borden KL. Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4E. Proc Natl Acad Sci USA 2010;107:5441–5446.
   PubMed Web of Science ®Google Scholar
• von Der Haar T, Ball PD, McCarthy JE. Stabilization of eukaryotic initiation factor 4E binding to the mRNA 5′-cap by domains of eIF4G. J Biol Chem 2000;275:30551–30555.
   PubMed Web of Science ®Google Scholar
• Brown CJ, Verma CS, Walkinshaw MD, Lane DP. Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around the cap-binding site. Cell Cycle 2009;8:1905–1911.
   PubMed Web of Science ®Google Scholar
• Tan K, Culjkovic B, Amri A, Borden KL. Ribavirin targets eIF4E dependent Akt survival signaling. Biochem Biophys Res Commun 2008;375:341–345.
   PubMed Web of Science ®Google Scholar
• Culjkovic B, Tan K, Orolicki S, Amri A, Meloche S, Borden KL. The eIF4E RNA regulon promotes the Akt signaling pathway. J Cell Biol 2008;181:51–63.
   PubMed Web of Science ®Google Scholar
• Jeney A, Kenessey I, Timar F, et al [Study of drugs against neoplastic metastasis]. Magy Onkol 2006;50:93–100.
   PubMedGoogle Scholar
• Graff JR, Konicek BW, Vincent TM, et al Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007;117:2638–2648.
   PubMed Web of Science ®Google Scholar
• Weber G. Metabolic regulation and chemotherapy. Adv Enzyme Regul 2006;46:26–32.
   PubMedGoogle Scholar
• Streeter DG, Witkowski JT, Khare GP, et al Mechanism of action of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci USA 1973;70:1174–1178.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Natsumeda Y, Weber G. Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase. Biochemistry 1988;27:2193–2196.
   PubMed Web of Science ®Google Scholar
• Gebeyehu G, Marquez VE, Van Cott A, et al Ribavirin, tiazofurin, and selenazofurin: mononucleotides and nicotinamide adenine dinucleotide analogues. Synthesis, structure, and interactions with IMP dehydrogenase. J Med Chem 1985;28:99–105.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Pawlak K, Nguyen BT, Robins RK, Sadee W. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture. Cancer Res 1985;45:5512–5520.
   PubMed Web of Science ®Google Scholar
• Wright DG, Boosalis MS, Waraska K, Oshry LJ, Weintraub LR, Vosburgh E. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis. Anticancer Res 1996;16:3349–3351.
   PubMed Web of Science ®Google Scholar
• Wright DG, Boosalis M, Malek K, Waraska K. Effects of the IMP-dehydrogenase inhibitor, tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies. Leuk Res 2004;28:1137–1143.
   PubMed Web of Science ®Google Scholar
• Malek K, Boosalis MS, Waraska K, Mitchell BS, Wright DG. Effects of the IMP-dehydrogenase inhibitor, tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies. Leuk Res 2004;28:1125–1136.
   PubMed Web of Science ®Google Scholar
• Natsumeda Y, Yamada Y, Yamaji Y, Weber G. Synergistic cytotoxic effect of tiazofurin and ribavirin in hepatoma cells. Biochem Biophys Res Commun 1988;153:321–327.
   PubMed Web of Science ®Google Scholar
• Lavrnja I, Stojkov D, Pekovic S, et al Combination of nucleoside analogues tiazofurin and ribavirin downregulates experimental autoimmune encephalomyelitis. Ann NY Acad Sci 2005;1048:392–395.
   PubMed Web of Science ®Google Scholar
• Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000;118:346–355.
   PubMed Web of Science ®Google Scholar
• Chiang DJ, Ye YL, Chen WL, Lee YL, Hsu NY, Chiang BL. Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation. Am J Respir Crit Care Med 2003;168:575–580.
   PubMed Web of Science ®Google Scholar
• Fiedler MA, Wernke-Dollries K, Stark JM. Inhibition of viral replication reverses respiratory syncytial virus-induced NF-kappaB activation and interleukin-8 gene expression in A549 cells. J Virol 1996;70:9079–9082.
   PubMed Web of Science ®Google Scholar
• Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999;19(Suppl. 1):17–24.
   PubMed Web of Science ®Google Scholar
• Patil SD, Ngo LY, Glue P, Unadkat JD. Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter. Pharm Res 1998;15:950–952.
   PubMed Web of Science ®Google Scholar
• Jarvis SM, Thorn JA, Glue P. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J Pharmacol 1998;123:1587–1592.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Kuniki K, Takekuma Y, Hirano T, Iseki K, Sugawara M. Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters. Eur J Pharmacol 2007;557:1–8.
   PubMed Web of Science ®Google Scholar
• Willis RC, Carson DA, Seegmiller JE. Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci USA 1978;75:3042–3044.
   PubMed Web of Science ®Google Scholar
• Wu JZ, Larson G, Walker H, Shim JH, Hong Z. Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5′-nucleotidase II: implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother 2005;49:2164–2171.
   PubMed Web of Science ®Google Scholar
• Sakowicz M, Grden M, Pawelczyk T. Expression level of adenosine kinase in rat tissues. Lack of phosphate effect on the enzyme activity. Acta Biochim Pol 2001;48:745–754.
   PubMed Web of Science ®Google Scholar
• Page T, Connor JD. The metabolism of ribavirin in erythrocytes and nucleated cells. Int J Biochem 1990;22:379–383.
   PubMedGoogle Scholar
• Miller JP, Kigwana LJ, Streeter DG, Robins RK, Simon LN, Roboz J. The relationship between the metabolism of ribavirin and its proposed mechanism of action. Ann NY Acad Sci 1977;284:211–229.
   PubMed Web of Science ®Google Scholar
• Lin CC, Luu K, Lourenco D, Yeh LT. Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. Antimicrob Agents Chemother 2003;47:2458–2463.
   PubMed Web of Science ®Google Scholar
• Traut TW. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 1994;140:1–22.
   PubMed Web of Science ®Google Scholar
• Smee DF, Matthews TR. Metabolism of ribavirin in respiratory syncytial virus-infected and uninfected cells. Antimicrob Agents Chemother 1986;30:117–121.
   PubMed Web of Science ®Google Scholar
• Zimmerman TP, Deeprose RD. Metabolism of 5-amino-1-beta-D-ribofuranosylimidazole-4-carboxamide and related five-membered heterocycles to 5′-triphosphates in human blood and L5178Y cells. Biochem Pharmacol 1978;27:709–716.
   PubMed Web of Science ®Google Scholar
• Kirsi JJ, North JA, McKernan PA, et al Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrob Agents Chemother 1983;24:353–361.
   PubMed Web of Science ®Google Scholar
• Taylor MW, Grosse WM, Schaley JE, et al Global effect of PEG-IFN-alpha and ribavirin on gene expression in PBMC in vitro. J Interferon Cytokine Res 2004;24:107–118.
   PubMed Web of Science ®Google Scholar
• Goswami BB, Borek E, Sharma OK, Fujitaki J, Smith RA. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem Biophys Res Commun 1979;89:830–836.
   PubMed Web of Science ®Google Scholar
• Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol 2006;175:415–426.
   PubMed Web of Science ®Google Scholar
• Rosenwald IB, Koifman L, Savas L, Chen JJ, Woda BA, Kadin ME. Expression of the translation initiation factors eIF-4E and eIF-2* is frequently increased in neoplastic cells of Hodgkin lymphoma. Hum Pathol 2008;39:910–916.
   PubMed Web of Science ®Google Scholar
• Wang S, Rosenwald IB, Hutzler MJ, et al Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas. Am J Pathol 1999;155:247–255.
   PubMed Web of Science ®Google Scholar
• Inamdar KV, Romaguera JE, Drakos E, et al Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine. Cancer 2009;115:4727–4736.
   PubMed Web of Science ®Google Scholar
• Sorrells DL Jr, Ghali GE, De Benedetti A, Nathan CO, Li BD. Progressive amplification and overexpression of the eukaryotic initiation factor 4E gene in different zones of head and neck cancers. J Oral Maxillofac Surg 1999;57:294–299.
   PubMed Web of Science ®Google Scholar
• Sorrells DL, Ghali GE, Meschonat C, et al Competitive PCR to detect eIF4E gene amplification in head and neck cancer. Head Neck 1999;21:60–65.
   PubMed Web of Science ®Google Scholar
• Nathan CO, Franklin S, Abreo FW, Nassar R, De Benedetti A, Glass J. Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J Clin Oncol 1999;17:2909–2914.
   PubMed Web of Science ®Google Scholar
• Nathan CA, Liu L, Li BD, Abreo FW, Nandy I, De Benedetti A. Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer. Oncogene 1997;15:579–584.
   PubMed Web of Science ®Google Scholar
• Sorrells DL, Black DR, Meschonat C, et al Detection of eIF4E gene amplification in breast cancer by competitive PCR. Ann Surg Oncol 1998;5:232–237.
   PubMed Web of Science ®Google Scholar
• Li BD, Gruner JS, Abreo F, et al Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg 2002;235:732–738; discussion 738–739.
   PubMed Web of Science ®Google Scholar
• Holm N, Byrnes K, Johnson L, et al A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer. Ann Surg Oncol 2008;15:3207–3215.
   PubMed Web of Science ®Google Scholar
• Byrnes K, White S, Chu Q, et al High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann Surg 2006;243:684–690; discussion 691–692.
   PubMed Web of Science ®Google Scholar
• Li BD, McDonald JC, Nassar R, De Benedetti A. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann Surg 1998;227:756–76l; discussion 761–763.
   PubMed Web of Science ®Google Scholar
• Li BD, Liu L, Dawson M, De Benedetti A. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 1997;79:2385–2390.
   PubMed Web of Science ®Google Scholar
• McClusky DR, Chu Q, Yu H, et al A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann Surg 2005;242:584–590; discussion 590–592.
   Google Scholar
• Rosenwald IB, Chen JJ, Wang S, Savas L, London IM, Pullman J. Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 1999;18:2507–2517.
   PubMed Web of Science ®Google Scholar
• Chen CN, Hsieh FJ, Cheng YM, Lee PH, Chang KJ. Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome. J Surg Oncol 2004;86:22–27.
   Google Scholar
• Mishra R, Miyamoto M, Yoshioka T, et al Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo. Int J Oncol 2009;34:1231–1240.
   PubMed Web of Science ®Google Scholar
• Rosenwald IB, Hutzler MJ, Wang S, Savas L, Fraire AE. Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung. Cancer 2001;92:2164–2171.
   PubMed Web of Science ®Google Scholar
• Seki N, Takasu T, Mandai K, et al Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clin Cancer Res 2002;8:3046–3053.
   PubMed Web of Science ®Google Scholar
• Wang R, Geng J, Wang JH, Chu XY, Geng HC, Chen LB. Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma. Lung Cancer 2009;66:237–244.
   PubMed Web of Science ®Google Scholar
• Yang SX, Hewitt SM, Steinberg SM, Liewehr DJ, Swain SM. Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncol Rep 2007;17:281–287.
   Google Scholar
• Khoury T, Alrawi S, Ramnath N, et al Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer. Clin Lung Cancer 2009;10:58–66.
   PubMed Web of Science ®Google Scholar
• Crew JP, Fuggle S, Bicknell R, Cranston DW, de Benedetti A, Harris AL. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer 2000;82:161–166.
   PubMed Web of Science ®Google Scholar
• Tejada S, Lobo MV, Garcia-Villanueva M, et al Eukaryotic initiation factors (eIF) 2alpha and 4E expression, localization, and phosphorylation in brain tumors. J Histochem Cytochem 2009;57:503–512.
   PubMed Web of Science ®Google Scholar
• Graff JR, Konicek BW, Lynch RL, et al eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 2009;69:3866–3873.
   PubMed Web of Science ®Google Scholar
• Wang S, Lloyd RV, Hutzler MJ, et al Expression of eukaryotic translation initiation factors 4E and 2alpha correlates with the progression of thyroid carcinoma. Thyroid 2001;11:1101–1107.
   PubMed Web of Science ®Google Scholar
• Matthews-Greer J, Caldito G, de Benedetti A, et al eIF4E as a marker for cervical neoplasia. Appl Immunohistochem Mol Morphol 2005;13:367–370.
   PubMedGoogle Scholar
• Van Trappen PO, Ryan A, Carroll M, et al A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. Br J Cancer 2002;87:537–544.
   PubMed Web of Science ®Google Scholar
• Lee JW, Choi JJ, Lee KM, et al eIF-4E expression is associated with histopathologic grades in cervical neoplasia. Hum Pathol 2005;36:1197–1203.
   PubMed Web of Science ®Google Scholar
• Noske A, Lindenberg JL, Darb-Esfahani S, et al Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep 2008;20:1409–1417.
   PubMed Web of Science ®Google Scholar